Project Details
Description
Early diagnosis and treatment are essential for preventing the progression of ARF to RHD. Currently, there are no specific treatments or vaccines available to stop ARF/RHD. It is hypothesised that treatment of ARF/RHD with sulphonylureas prevents the development of cardiac damage and further disease progression. Therefore, this study aims to determine the efficacy of Glyburide (a sulphonylurea) and its derivative, MCC950, as a targeted therapy for ARF/RHD using the RHD rat model developed at UNE.
Funding
Funder: University of New England
Award Value: $9,245
Award Value: $9,245
| Status | Finished |
|---|---|
| Effective start/end date | 1/01/25 → 31/12/25 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.